Exagen Inc.

Contributing Author

Recent Articles by Exagen Inc.

8 hours	Exagen to Announce Third Quarter Financial Results on November 10, 2026 XGN GlobeNewswire
Aug-04	Exagen Inc. Reports Second Quarter 2026 Financial Results XGN +37.82% GlobeNewswire
Jul-28	Exagen Inc. to Participate in Upcoming Investor Conference XGN GlobeNewswire
Jul-21	Exagen to Announce Second Quarter Financial Results on August 4, 2026 XGN GlobeNewswire
Jun-01	Exagen Announces Publication of Systematic Review Confirming Robust Real-World Performance of AVISE Lupus XGN +7.43% GlobeNewswire
May-11	Exagen Inc. Reports First Quarter 2026 Results XGN +34.92% GlobeNewswire
Apr-27	Exagen Inc. to Announce First Quarter Financial Results on May 11, 2026 XGN GlobeNewswire
Mar-10	Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2025 Results XGN GlobeNewswire
Mar-03	Exagen Inc. to Participate in Upcoming Investor Conferences XGN GlobeNewswire
Feb-24	Exagen Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026 XGN GlobeNewswire
Jan-11	Exagen Inc. Announces Select Preliminary 2025 Financial Results XGN GlobeNewswire
Nov-11	Exagen Inc. to Participate in Fourth Quarter Investor Conferences XGN GlobeNewswire
Nov-04	Exagen Inc. Reports Strong Q3 2025 Results XGN -8.96% GlobeNewswire
Oct-23	Exagen Announces Acceptance of Six Abstracts at 2025 American College of Rheumatology Convergence XGN GlobeNewswire
Oct-21	Exagen Inc. to Announce Third Quarter 2025 Financial Results on November 4, 2025 XGN GlobeNewswire
Aug-06	Exagen Inc. to Participate in Third Quarter Investor Conferences XGN GlobeNewswire
Jul-29	Exagen Inc. Reports Strong Q2 2025 Results XGN +14.34% GlobeNewswire
Jul-17	Exagen Inc. Appoints Chas McKhann to Board of Directors XGN GlobeNewswire
Jul-15	Exagen Inc. to Announce Second Quarter 2025 Financial Results on July 29, 2025 XGN GlobeNewswire
Jun-23	Michael Mahler, PhD Joins Exagen as Chief Scientific Officer to Enhance Leadership in Autoimmune Diagnostics XGN GlobeNewswire
May-09	Exagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter's Option to Purchase Additional Shares XGN -7.31% GlobeNewswire
May-08	Exagen Inc. Prices Public Offering of Common Stock XGN -9.81% GlobeNewswire
May-07	Exagen Inc. Announces Proposed Public Offering of Common Stock XGN +6.39% GlobeNewswire
May-05	Exagen Inc. Reports Record Q1 2025 Revenue Driven by Growth in Average Selling Price and Testing Volume XGN GlobeNewswire

Exagen Inc.

Recent Articles by Exagen Inc.

Upgrade your Finviz experience